AUTHOR INDEX

ABBOTT, M. *see* LEATHARD, H.L.
ABUBAKAR, I., ALIYU, S.H., ARUMUGAM, C., USMAN, N.K. & HUNTER, P.R. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis: 387
ABURUZ, S., HEANEY, L.G., MILLERSHIP, J., GAMBLE, J. & MCELNAY, J. A cross-sectional study evaluating the relationship between cortisol suppression and asthma control in patients with difficult asthma: 110
ACKERS, R., MURRAY, M.L., BESAG, F.M.C. & WONG, I.C.K. Prioritizing children's medicines for research: a pharmacoepidemiological study of antiepileptic drugs: 689
AGERSØ, H. *see* TORNØE, C.W.
AGORAM, B., SUTJANDRA, L. & SULLIVAN, J.T. Population pharmacokinetics of darbepoetin alfa in healthy subjects: 41
AKIZAWA, T. *see* TAKAMA, H.
ALIYU, S.H. *see* ABUBAKAR, I.
ALLEGAERT, K. *see* ANDERSON, B.J.
AL-ROOMI, K. *see* PRASAD, K.
AMIN, D.M. *see* MANT, T.G.K.
ANDERSON, B.J., ALLEGAERT, K., VAN DEN ANKER, J.N., COSSEY, V. & HOLFORD, N.H.G. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance: 75
AREFAYENE, M. *see* SHIN, J.-G.
ARONSON, J.K. Adverse drug reactions – no farewell to harms: 131
ARONSON, J.K. Communicating information about drug interactions: 637
ARONSON, J.K. Compliance, concordance, adherence: 383
ARONSON, J.K. Concentration-effect and dose-response relations in clinical pharmacology: 255
ARONSON, J.K. Drug therapy in kidney disease: 509
ARONSON, J.K., LENNARD, M.S., RITTER, J.M., BEGG, E.J., LEWIS, L.D. & SCHACHTER, M. Editors' review of 2006 and the BJCP prize: 1
ARORA, M. *see* PRAHARAJ, S.K.
ARUMUGAM, C. *see* ABUBAKAR, I.
ARUNA, D. & NAIDU, M.U.R. Pharmacodynamic interaction studies of *Ginkgo biloba* with cilostazol and clopidogrel in healthy human subjects: 333
ASAI, F. *see* JAKUBOWSKI, J.A.
ASIMUS, S. & GORDI, T. Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model: 758
ATTHOBARI, J., GANSEVOORT, R.T., VISSER, S.T., DE JONG, P.E. & de JONG-VAN DEN BERG, L.T.W. The impact of hormonal contraceptives on blood pressure, urinary albumin excretion and glomerular filtration rate: 224
AVERY, A.J. *see* HOWARD, R.L.
AYDT, E. *see* MEYER, M.
AZOULAY, L. *see* BÉRARD, A.

BALAKRISHNAN, K., TORDOFF, J., NORRIS, P. & REITH, D. Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998–2002: 85
BALDESSARINI, R.J. *see* SIM, K.
BANFIELD, C. *see* GUPTA, S.
BARBANOJ, M.J. *see* MOLTÓ, J.
BARSHOP, B.A. *see* FIDLER, M.C.
BÉRARD, A. *see* BOUCHARD, M.-H.
BÉRARD, A., AZOULAY, L., KOREN, G., BLAIS, L., PERREAULT, S. & ORAICHI, D. Isotretinoin, pregnancies, abortions and birth defects: a populationbased perspective: 196
BECKA, M. *see* KUBITZA, D.
BEDDING, A.W. *see* FORGUE, S.T.
BEEH, K.-M. *see* MEYER, M.
BEGG, E.J. *see* ARONSON, J.K.
BEGG, E.J. *see* VELLA-BRINCAT, J.W.A.
BEIER, J. *see* MEYER, M.
BELL, S.C. *see* HENNIG, S.
BENGTSSON, T. *see* BONDESSON, E.
BENNDORF, R. *see* KOM, G.D.
BENNETT, K. *see* USHER, C.
BERTINO, J.S. *see* CHEN, Y.-C.
BESAG, F.M.C. *see* ACKERS, R.
BEYER, D. *see* MEYER, M.
BIANCHETTI, M.G. *see* MEIER, C.M.
BLACK, J.W. *see* GERSKOWITCH, V.P.
BLAIS, L. *see* BÉRARD, A.
BLAIS, L. *see* BOUCHARD, M.-H.
BLANCO, A. *see* MOLTÓ, J.
BLENKINSOPP, A., WILKIE, P., WANG, M. & ROUTLEDGE, P.A. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience: 148
BLIX, H.S. *see* VIKTIL, K.K.
BLUME, H. *see* NASSR, N.
BÖGER, R.H. *see* KOM, G.D.
BONDESSON, E., BENGTSSON, T., NILSSON, L.-E. & WOLLMER, P. Site of deposition and absorption of an inhaled hydrophilic solute: 722
BOUCHARD, M.-H., DRAGOMIR, A., BLAIS, L., BÉRARD, A., PILON, D. & PERREAULT, S. Impact of adherence to statins on coronary artery disease in primary prevention: 698
BOUW, R. *see* VAN HEST, R.M.
BRADFORD, D. *see* MANT, T.G.K.
BRAMELD, K. *see* ZHANG, M.
BRAMSON, C. *see* OUELLET, D.
BRANCH, L.G. *see* FRENCH, D.D.
BRANCH, R.A. *see* ZGHEIB, N.K.
BRANDT, J.T. *see* JAKUBOWSKI, J.A.
BROWNSELL, M. *see* LEATHARD, H.L.
BRYANT, L. *see* NGUYEN, N.Q.
BURGER, D.M. *see* SKOWRON, G.
BURGGRAAF, J. *see* VAN DOORN, M.
BURGSTAD, C. *see* NGUYEN, N.Q.

CAFFO, B. *see* NDOVI, T.T.
CAMPA, C. *see* COSTAGLIOLA, C.
CAMPBELL, R. *see* FRENCH, D.D.
CHAMBERS, S.T. *see* VELLA-BRINCAT, J.W.A.
CHAN, C., YEO, K.P., PAN, A.X., LIM, M., KNADLER, M.P. & SMALL, D.S. Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects: 310
CHAN, Y.H. *see* SIM, K.
CHAPMAN, M. *see* NGUYEN, N.Q.
CHARLES, B.G. *see* HENNIG, S.
CHARMES, J.-P. *see* LAROCHE, M.-L.
CHEN, Y.-C., NAFZIGER, A.N., BERTINO, J.S. & KASHUBA, A.D.M. Authors' response: Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment: 633
CHIU, Y.-Y., ROTH, M.D., KOLIS, S., ROGOVITZ, D. & DAVIES, B. Pharmacokinetics of a novel agent, R667, in patients with emphysema: 527
CHO, K.-H. *see* SHIN, J.-G.
CHOI, L. *see* NDOVI, T.T.
CHONG, K.T., HO, W.F., KOO, S.H., THOMPSON, P. & LEE, E.J.D. Distribution of the FcγRIIIa 176 F/V polymorphism amongst healthy Chinese, Malays and Asian Indians in Singapore: 328
CHONG, M.-Y. *see* SIM, K.
CHUA, H.C. *see* SIM, K.
CHUNG, E.K. *see* SIM, K.
CLARKE, S.J. *see* LI, K.M.
CLEUREN, G. *see* DOBRE, D.
CLOTET, B. *see* MOLTÓ, J.
COCHAT, P. *see* NGUYEN, K.-A.
COHEN, A. *see* VAN DOORN, M.
COMBS, M. *see* STYPINSKI, D.
CONIL, J.M., GEORGES, B., FOURCADE, O., SEGUIN, T., LAVIT, M., SAMII, K., HOUIN, G., TACK, I. & SAIVIN, S.

© 2007 Blackwell Publishing Ltd

Assessment of renal function in clinical practice at the bedside of burn patients: 583
CONNELL, J. *see* SARGENTINI-MAIER, M.L.
CONSTABLE, S., HAM, A. & PIRMOHAMED, M. Herbal medicines and acute medical emergency admissions to hospital: 247
COSSEY, V. *see* ANDERSON, B.J.
COSTAGLIOLA, C., CAMPA, C., PARMEGGIANI, F., INCORVAIA, C., PERRI, P., D'ANGELO, S., LAMBERTI, G. & SEBASTIANI, A. Effect of 2% dorzolamide on retinal blood flow: a study on juvenile primary open-angle glaucoma patients already receiving 0.5% timolol: 376
CUNNINGHAM, F. *see* FRENCH, D.D.
CURRIE, G.P., NIRUBAN, A. & DEMPSEY, O.J. A rare cause of finger clubbing in a life-long nonsmoker: 252
CUTLER, D. *see* GUPTA, S.

D'ANGELO, S. *see* COSTAGLIOLA, C.
DAVIES, B. *see* CHIU, Y.-Y.
DAY, R.O. *see* MINERS, J.O.
DE BRUIN, M.L., LANGENDIJK, P.N.J., KOOPMANS, R.P., WILDE, A.A.M., LEUFKENS, H.G.M. & HOES, A.W. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs: 216
DE JONG, P.E. *see* ATTHOBARI, J.
DE JONG-VAN DEN BERG, L.T.W. *see* ATTHOBARI, J.
DE PONTI, F. *see* POLUZZI, E.
DE SMET, P.A.G.M. Clinical risk management of herb–drug interactions: 258
DEJONGSTE, M.J.L. *see* DOBRE, D.
DELAVARGA, M. *see* MOLTÓ, J.
DEMPSEY, O.J. *see* CURRIE, G.P.
DEUTSCH, R. *see* FIDLER, M.C.
DI MARCO, M. *see* MARIER, J.-F.
DOBRE, D., DEJONGSTE, M.J.L., LUCAS, C., CLEUREN, G., VAN VELDHUISEN, D.J., RANCHOR, A.V. & HAAIJER-RUSKAMP, F. Effectiveness of β-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age?: 356
DOHIL, R. *see* FIDLER, M.C.
DRAGOMIR, A. *see* BOUCHARD, M.-H.
DUFFULL, S.B. *see* HENNIG, S.

ECCLES, R. Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse: 10
ELLINGTON, C., GRGURINOVICH, N., MINERS, J.O. & MANGONI, A.A. Quality of requests for serum digoxin concentrations: experience from an Australian Regional Health Service: 623
ERB, K.A. *see* NASSR, N.

FEELY, J. *see* USHER, C.
FENSKE, M. Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment: 632
FIDLER, M.C., BARSHOP, B.A., GANGOITI, J.A., DEUTSCH, R., MARTIN, M., SCHNEIDER, J.A. & DOHIL, R. Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion: 36
FIGUERAS, A. *see* MALDONADO, J.-C.
FLANAGAN, R. *see* TIMBRELL, J.
FLOCKHART, D.A. *see* SHIN, J.-G.
FORGUE, S.T., PHILLIPS, D.L., BEDDING, A.W., PAYNE, C.D., JEWELL, H., PATTERSON, B.E., WRISHKO, R.E. & MITCHELL, M.I. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics: 24
FOSSALI, E. *see* MEIER, C.M.
FOURCADE, O. *see* CONIL, J.M.
FRANCE, M. *see* HENNIG, S.
FRASER, R.J. *see* NGUYEN, N.Q.
FREDRIKSON, H. *see* LILJA, J.J.
FREESTONE, S. *see* JAKUBOWSKI, J.A.
FRENCH, D.D., CAMPBELL, R., SPEHAR, A., RUBENSTEIN, L.Z., BRANCH, L.G. & CUNNINGHAM, F. National outpatient medication profiling: medications associated with outpatient fractures in community-dwelling elderly veterans: 238
FRYE, R.F. *see* ZGHEIB, N.K.
FUJII, S. *see* SIM, K.
FUMAZ, C.R. *see* MOLTÓ, J.

GALLAGHER, K. *see* VELLA-BRINCAT, J.W.A.
GAMBLE, J. *see* ABURUZ, S.
GANGOITI, J.A. *see* FIDLER, M.C.
GANSEVOORT, R.T. *see* ATTHOBARI, J.
GARDNER, M. *see* OUELLET, D.
GEORGE, J. & SHALANSKY, S.J. Predictors of refill non-adherence in patients with heart failure: 488
GEORGE, J., MUNRO, K., MCCAIG, D. & STEWART, D. Risk factors for medication misadventure among residents in sheltered housing complexes: 171
GEORGES, B. *see* CONIL, J.M.
GERSKOWITCH, V.P., HODGE, J., HULL, R.A.D., SHANKLEY, N.P., KALINDJIAN, S.B., MCEWEN, J. & BLACK, J.W. Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist: 618
GHIGLIA, S. *see* MEIER, C.M.
GIRBES, A.R.J. *see* VAN ZANTEN, A.R.H.
GOGGIN, T. *see* VAN HEST, R.M.
GOMENI, R. & MERLO-PICH, E. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials: 595
GORDI, T. *see* ASIMUS, S.
GORDON, R. *see* VAN HEST, R.M.
GRGURINOVICH, N. *see* ELLINGTON, C.
GRIBNAU, F.W.J. *see* VAN LUIJN, J.C.F.
GUDE, N.M. *see* SUDHAKARAN, S.
GUEYFFIER, F. *see* NGUYEN, K.-A.
GUO, R.-C. *see* SUN, D.-Q.
GUPTA, S., JEN, J., KOLZ, K. & CUTLER, D. Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia: 292
GUPTA, S., KHALILIEH, S., KANTESARIA, B. & BANFIELD, C. Pharmacokinetics of desloratadine in children between 2 and 11 years of age: 534

HAAIJER-RUSKAMP, F. *see* DOBRE, D.
HACKETT, L.P. *see* ILETT, K.F.
HACKETT, L.P. *see* KRISTENSEN, J.H.
HALL, J.M. The BPS Diploma in Advanced Pharmacology: a training opportunity for clinical pharmacologists: 385
HALL, W. *see* MANT, A.
HAM, A. *see* CONSTABLE, S.
HAWKEY, C.J. Authors' reply: Nonselective nonsteroidal anti-inflammatory drugs and increased cardiovascular events: stress could be the explanation: 502
HAYASHI, N., TSUKAMOTO, Y., SALLAS, W.M. & LOWE, P.J. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab: 548
HAZUI, T. *see* HORI, S.
HE, Y.L. *see* SIM, K.
HEANEY, L.G. *see* ABURUZ, S.
HENDRIX, C.W. *see* NDOVI, T.T.
HENNIG, S., WATERHOUSE, T.H., BELL, S.C., FRANCE, M., WAINWRIGHT, C.E., MILLER, H., CHARLES, B.G. & DUFFULL, S.B. A D-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients: 438
HERMANN, R. *see* NASSR, N.
HIROTA, T. *see* JAKUBOWSKI, J.A.
HO, W.F. *see* CHONG, K.T.
HODGE, J. *see* GERSKOWITCH, V.P.
HOES, A.W. *see* DE BRUIN, M.L.
HOGG, J.S. *see* MULRENNAN, S.A.
HOLFORD, N.H.G. *see* ANDERSON, B.J.
HOLLOWAY, R.H. *see* NGUYEN, N.Q.
HOLMAN, C.D.J. *see* ZHANG, M.
HOLOHAN, P.D. *see* LAROCCA, D.
HORI, S., MATSUO, N., YAMAMOTO, A.,

HAZUI, T., YAGI, H., NAKANO, M., SUZUKI, Y., MIKI, A., OHTANI, H. & SAWADA, Y. Piloerection induced by replacing fluvoxamine with milnacipran: 665
HOSKINS, J. *see* LI, K.M.
HOUIN, G. *see* CONIL, J.M.
HOWARD, R.L., AVERY, A.J., SLAVENBURG, S., ROYAL, S., PIPE, G., LUCASSEN, P. & PIRMOHAMED, M. Which drugs cause preventable admissions to hospital? A systematic review: 136
HU, P. *see* ZHAO, Q.
HULL, R.A.D. *see* GERSKOWITCH, V.P.
HUNTER, P.R. *see* ABUBAKAR, I.

ILETT, K.F. *see* KRISTENSEN, J.H.
ILETT, K.F., HACKETT, L.P., KRISTENSEN, J.H. & KOHAN, R. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder: 371
INCORVAIA, C. *see* COSTAGLIOLA, C.
ISHIKAWA, H. *see* STYPINSKI, D.
ITO, K., OHTANI, H. & SAWADA, Y. Assessment of α_1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory: 394
IVERSEN, L. & WHELPTON, R. Speed, Ecstasy, Ritalin: The Science of Amphetamines: 763

JACOBS, T. *see* SARGENTINI-MAIER, M.L.
JAKUBOWSKI, J.A., MATSUSHIMA, N., ASAI, F., NAGANUMA, H., BRANDT, J.T., HIROTA, T., FREESTONE, S. & WINTERS, K.J. A multiple dose study of prasugrel (CS-747), a novel thienopyridine $P2Y_{12}$ inhibitor, compared with clopidogrel in healthy humans: 421
JEN, J. *see* GUPTA, S.
JEWELL, H. *see* FORGUE, S.T.
JHAJ, R. *see* SADASIVAM, B.
JIANG, J. *see* ZHAO, Q.
JILMA, B. *see* MEYER, M.
JONSSON, E.N. *see* TORNØE, C.W.

KALINDJIAN, S.B. *see* GERSKOWITCH, V.P.
KAMBAYASHI, Y. *see* MANT, T.G.K.
KANG, W.-K. *see* SHIN, J.-G.
KANTESARIA, B. *see* GUPTA, S.
KARLSSON, M.O. *see* TORNØE, C.W.
KASHUBA, A.D.M. *see* CHEN, Y.-C.
KASSAÏ, B. *see* NGUYEN, K.-A.
KHALILIEH, S. *see* GUPTA, S.
KIM, D.-I. *see* SHIN, J.-G.
KIM, D.-S. *see* SHIN, J.-G.
KIM, K.-A. *see* SHIN, J.-G.
KIM, K.-A., PARK, P.-W. & PARK, J.-Y. Effect of *ABCB1* (*MDR1*) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects: 53
KIM, K.-A., PARK, P.-W., KIM, K.R. & PARK, J.-Y. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans: 339
KIM, K.R. *see* KIM, K.-A.
KIRKPATRICK, C.M.J. *see* VELLA-BRINCAT, J.W.A.
KNADLER, M.P. *see* CHAN, C.
KNIGHTS, K.M., MANGONI, A.A. & MINERS, J.O. Authors' reply: Nonselective nonsteroidal anti-inflammatory drugs and increased cardiovascular events: emotional stress could be the explanation: 502
KNOERZER, D. *see* NASSR, N.
KOHAN, R. *see* ILETT, K.F.
KOHAN, R. *see* KRISTENSEN, J.H.
KOLIS, S. *see* CHIU, Y.-Y.
KOLZ, K. *see* GUPTA, S.
KOM, G.D., SCHWEDHELM, E., MAAS, R., SCHNEIDER, L., BENNDORF, R. & BÖGER, R.H. Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F_{2trans}-isoprostane in hypercholesterolaemic patients: 672
KONG, D.C.M. *see* SUDHAKARAN, S.
KOO, S.H. *see* CHONG, K.T.
KOOPMANS, R.P. *see* DE BRUIN, M.L.
KOREN, G. *see* BÉRARD, A.
KOSHIKAWA, S. *see* TAKAMA, H.
KRISHNAN, P.R. *see* PRASAD, K.
KRISTENSEN, J.H. *see* ILETT, K.F.
KRISTENSEN, J.H., ILETT, K.F., RAMPONO, J., KOHAN, R. & HACKETT, L.P. Transfer of the antidepressant mirtazapine into breast milk: 322
KUBITZA, D., BECKA, M., MUECK, W. & ZUEHLSDORF, M. Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen: 469
KUYPERS, D. *see* NAESENS, M.

LACOURCIERE, Y. *see* LEFEBVRE, J.
LAHEIJ, R.J.F. *see* VAN OIJEN, M.G.H.
LAHU, G. *see* NASSR, N.
LAINE, K. *see* SAARI, T.I.
LAMBERTI, G. *see* COSTAGLIOLA, C.
LANGENDIJK, P.N.J. *see* DE BRUIN, M.L.
LAROCCA, D., LEHMANN, D.F., PERL, A., OZAWA, T. & HOLOHAN, P.D. The combination of nuclear and mitochondrial mutations as a risk factor for idiosyncratic toxicity: 249
LAROCHE, M.-L., CHARMES, J.-P., NOUAILLE, Y., PICARD, N. & MERLE, L. Is inappropriate medication use a major cause of adverse drug reactions in the elderly?: 177
LAVIT, M. *see* CONIL, J.M.
LAW, M.R., MORRIS, J.K. & WALD, N.J. Calcium channel blockers and headache: 157
LEATHARD, H.L., ABBOTT, M., BROWNSELL, M., LENNARD, M. & MAXWELL, S. Education for new prescribers: a summary of the proceedings of a symposium held at The British Pharmacological Society, December 2005: 5
LEE, E.J.D. *see* CHONG, K.T.
LEE, M.S. *see* SIM, K.
LEE, N.B. *see* SIM, K.
LEFEBVRE, J., POIRIER, L., POIRIER, P., TURGEON, J. & LACOURCIERE, Y. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension: 575
LEHMANN, D.F. *see* LAROCCA, D.
LEINO, K. *see* SAARI, T.I.
LENNARD, M. *see* LEATHARD, H.L.
LENNARD, M. *see* PHILLIPS, I.R.
LENNARD, M.S. *see* ARONSON, J.K.
LEUFKENS, H.G.M. *see* DE BRUIN, M.L.
LEUFKENS, H.G.M. *see* VAN LUIJN, J.C.F.
LEWIS, L.D. *see* ARONSON, J.K.
LI, J. *see* SUDHAKARAN, S.
LI, K.M., RIVORY, L.P., HOSKINS, J., SHARMA, R. & CLARKE, S.J. Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients: 67
LI, X.M. *see* ZHAO, Q.
LILJA, J.J., NIEMI, M., FREDRIKSON, H. & NEUVONEN, P.J. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide: 732
LIM, M. *see* CHAN, C.
LIMONI, C. *see* MEIER, C.M.
LOR, M. *see* MARIER, J.-F.
LOWE, P.J. *see* HAYASHI, N.
LOWINGER, J. *see* MANT, A.
LU, Z.S. *see* ZHAO, Q.
LUCAS, C. *see* DOBRE, D.
LUCASSEN, P. *see* HOWARD, R.L.

MAAS, R. *see* KOM, G.D.
MADSEN, H. *see* TORNØE, C.W.
MAHENDRAN, R. *see* SIM, K.
MALDONADO, J.-C., MELÉNDEZ, S.D. & FIGUERAS, A. Long-term effects of an educational intervention on selfmedication and appropriate drug use in single-sex secondary public schools, Quito, Ecuador: 92
MAMELOK, R.D. *see* VAN HEST, R.M.
MANGONI, A.A. *see* ELLINGTON, C.
MANGONI, A.A. *see* KNIGHTS, K.M.
MANGONI, A.A. *see* NGUYEN, N.Q.

MANT, A., LOWINGER, J., HALL, W., WHICKER, S., RINGLAND, C. & Stark, H. Statins down under: 125
MANT, T.G.K., BRADFORD, D., AMIN, D.M., PISUPATI, J., KAMBAYASHI, Y., YANO, Y., TANAKA, K. & YAMADA-SAWADA, T. Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers: 512
MARCHESINI, G. *see* POLUZZI, E.
MARIER, J.-F., LOR, M., MORIN, J., ROUX, L., DI MARCO, M., MORELLI, G. & SÆDDER, E.A. Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation: 121
MARIGNIER, S. *see* NGUYEN, K.-A.
MARTIN, M. *see* FIDLER, M.C.
MATHOT, R.A. *see* VAN HEST, R.M.
MATSUO, N. *see* HORI, S.
MATSUSHIMA, N. *see* JAKUBOWSKI, J.A.
MAXWELL, S. *see* LEATHARD, H.L.
MCCAIG, D. *see* GEORGE, J.
MCELNAY, J. *see* ABURUZ, S.
MCEWEN, J. *see* GERSKOWITCH, V.P.
MCQUAY, H.J. & MOORE, R.A. Dose–response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies: 271
MEIER, C.M., SIMONETTI, G.D., GHIGLIA, S., FOSSALI, E., SALICE, P., LIMONI, C. & BIANCHETTI, M.G. Palatability of angiotensin II antagonists among nephropathic children: 628
MELÉNDEZ, S.D. *see* MALDONADO, J.-C.
MERLE, L. *see* LAROCHE, M.-L.
MERLO-PICH, E. *see* GOMENI, R.
MEYER, M., BEEH, K.-M., BEIER, J., BEYER, D., AYDT, E., ZAHLTEN, R., JILMA, B. & WOLFF, G. Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males: 451
MIKI, A. *see* HORI, S.
MILLER, H. *see* HENNIG, S.
MILLERSHIP, J. *see* ABURUZ, S.
MILTON, A. *see* OUELLET, D.
MINERS, J.O. & DAY, R.O. Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes: 380
MINERS, J.O. *see* ELLINGTON, C.
MINERS, J.O. *see* KNIGHTS, K.M.
MIRANDA, C. *see* MOLTÓ, J.
MIRANDA, J. *see* MOLTÓ, J.
MITCHELL, M.I. *see* FORGUE, S.T.
MOGER, T.A. *see* VIKTIL, K.K.
MOLTÓ, J., BLANCO, A., MIRANDA, C., MIRANDA, J., PUIG, J., VALLE, M., DELAVARGA, M., FUMAZ, C.R., BARBANOJ, M.J. & CLOTET, B. Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice: 715
MONTANARO, N. *see* POLUZZI, E.
MOORE, R.A. *see* MCQUAY, H.J.
MORELLI, G. *see* MARIER, J.-F.
MORICE, A.H. *see* MULRENNAN, S.A.
MORIN, J. *see* MARIER, J.-F.
MORRIS, J.K. *see* LAW, M.R.
MOTOLA, D. *see* POLUZZI, E.
MUECK, W. *see* KUBITZA, D.
MULRENNAN, S.A., HOGG, J.S., TEOH, R.C. & MORICE, A.H. Adrenal axis suppression unrelated to the dynamics of dosing with beclomethasone monopropionate: 288
MUNRO, K. *see* GEORGE, J.
MURRAY, M.L. *see* ACKERS, R.

NAESENS, M., VERBEKE, K., VANRENTERGHEM, Y. & KUYPERS, D. Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients: 541
NAFZIGER, A.N. *see* CHEN, Y.-C.
NAGANUMA, H. *see* JAKUBOWSKI, J.A.
NAIDU, M.U.R. *see* ARUNA, D.
NAKANO, M. *see* HORI, S.
NAKASHIMA, D. *see* TAKAMA, H.
NASSR, N., LAHU, G., VON RICHTER, O., REUTTER, F., KNOERZER, D., ZECH, K., ERB, K.A., SCHUG, B., BLUME, H. & HERMANN, R. Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects: 365
NATION, R.L. *see* SUDHAKARAN, S.
NDOVI, T.T., PARSONS, T., CHOI, L., CAFFO, B., ROHDE, C. & HENDRIX, C.W. A new method to estimate quantitatively seminal vesicle and prostate gland contributions to ejaculate: 404
NEUVONEN, P.J. *see* LILJA, J.J.
NEUVONEN, P.J. *see* SAARI, T.I.
NEWBOLD, P., SANDERS, N. & REELE, S.B. Lack of correlation between exercise and sibenadet-induced changes in heart rate corrected measurement of the QT interval: 279
NGUYEN, K.-A., VIAL, T., GUEYFFIER, F., MARIGNIER, S., COCHAT, P. & KASSAÏ, B. Safety of computerized drug management: a case report: 245
NGUYEN, N.Q., MANGONI, A.A., FRASER, R.J., CHAPMAN, M., BRYANT, L., BURGSTAD, C. & HOLLOWAY, R.H. Prokinetic therapy with erythromycin has no significant impact on blood pressure and heart rate in critically ill patients: 498
NI, M.-Y. *see* SUN, D.-Q.
NIELSEN, H.A. *see* TORNØE, C.W.
NIEMI, M. *see* LILJA, J.J.
NILSSON, L.-E. *see* BONDESSON, E.
NIRUBAN, A. *see* CURRIE, G.P.
NOHLMANS-PAULSSEN, M.K.E. *see* VAN ZANTEN, A.R.H.
NORRIS, P. *see* BALAKRISHNAN, K.
NOUAILLE, Y. *see* LAROCHE, M.-L.

OBAIDI, M. *see* STYPINSKI, D.
OGATA, H. *see* TAKAMA, H.
OGDEN, R. *see* SKOWRON, G.
OHTANI, H. *see* HORI, S.
OHTANI, H. *see* ITO, K.
OLKKOLA, K.T. *see* SAARI, T.I.
ORAICHI, D. *see* BÉRARD, A.
OUDIJK, M. *see* VAN ZANTEN, A.R.H.
OUELLET, D., BRAMSON, C., ROMAN, D., REMMERS, A.E., RANDINITIS, E., MILTON, A. & GARDNER, M. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene: 59
OZAWA, T. *see* LAROCCA, D.

PAN, A.X. *see* CHAN, C.
PARK, J.-Y. *see* KIM, K.-A.
PARK, J.-Y. *see* KIM, K.-A.
PARK, P.-W. *see* KIM, K.-A.
PARK, P.-W. *see* KIM, K.-A.
PARMEGGIANI, F. *see* COSTAGLIOLA, C.
PARSONS, T. *see* NDOVI, T.T.
PATTERSON, B.E. *see* FORGUE, S.T.
PAYNE, C.D. *see* FORGUE, S.T.
PERL, A. *see* LAROCCA, D.
PERREAULT, S. *see* BÉRARD, A.
PERREAULT, S. *see* BOUCHARD, M.-H.
PERRI, P. *see* COSTAGLIOLA, C.
PETERS, W.H.M. *see* VAN OIJEN, M.G.H.
PHILLIPS, D.L. *see* FORGUE, S.T.
PHILLIPS, I.R. SHEPHARD, E.A. & LENNARD, M. Cytochrome P450 Protocols, 2nd edn: 764
PICARD, N. *see* LAROCHE, M.-L.
PIGEOLET, E. *see* SARGENTINI-MAIER, M.L.
PILON, D. *see* BOUCHARD, M.-H.
PIPE, G. *see* HOWARD, R.L.
PIRMOHAMED, M. *see* CONSTABLE, S.
PIRMOHAMED, M. *see* HOWARD, R.L.
PISUPATI, J. *see* MANT, T.G.K.
PO, A.L.W. Dose–response of minor analgesics in acute pain: 268
POIRIER, L. *see* LEFEBVRE, J.
POIRIER, P. *see* LEFEBVRE, J.
POLDERMAN, K.H. *see* VAN ZANTEN, A.R.H.
POLS, H.A.P. *see* VAN DER VELDE, N.
POLUZZI, E., STRAHINJA, P.,

VACCHERI, A., VARGIU, A., SILVANI, M.C., MOTOLA, D., MARCHESINI, G., DE PONTI, F. & MONTANARO, N. Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage: 346
PRAHARAJ, S.K. & ARORA, M. Amitriptyline for clozapine-induced nocturnal enuresis and sialorrhoea: 128
PRASAD, K., KRISHNAN, P.R., AL-ROOMI, K. & SEQUEIRA R. Anticonvulsant therapy for status epilepticus: 640
PREEN, D.B. *see* ZHANG, M.
PUIG, J. *see* MOLTÓ, J.

RAMPONO, J. *see* KRISTENSEN, J.H.
RANCHOR, A.V. *see* DOBRE, D.
RANDINITIS, E. *see* OUELLET, D.
RAYNER, C.R. *see* SUDHAKARAN, S.
REELE, S.B. *see* NEWBOLD, P.
REIKVAM, A. *see* VIKTIL, K.K.
REITH, D. *see* BALAKRISHNAN, K.
REMMERS, A.E. *see* OUELLET, D.
REUTTER, F. *see* NASSR, N.
RIETHUISEN, J.-M. *see* SARGENTINI-MAIER, M.L.
RINGLAND, C. *see* MANT, A.
RITTER, J.M. *see* ARONSON, J.K.
RIVORY, L.P. *see* LI, K.M.
ROGOVITZ, D. *see* CHIU, Y.-Y.
ROHDE, C. *see* NDOVI, T.T.
ROLAN, P. *see* SARGENTINI-MAIER, M.L.
ROMAN, D. *see* OUELLET, D.
ROMKES, M. *see* ZGHEIB, N.K.
ROTH, M.D. *see* CHIU, Y.-Y.
ROUTLEDGE, P.A. *see* BLENKINSOPP, A.
ROUX, L. *see* MARIER, J.-F.
ROYAL, S. *see* HOWARD, R.L.
RUBENSTEIN, L.Z. *see* FRENCH, D.D.

SÆDDER, E.A. *see* MARIER, J.-F.
SAARI, T.I., LAINE, K., LEINO, K., VALTONEN, M., NEUVONEN, P.J. & OLKKOLA, K.T. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects: 116
SADASIVAM, B. & JHAJ, R. Dysgeusia with amlodipine – a case report: 253
SAINZ-FUERTES, R. Robert William Kerwin: 765
SAIVIN, S. *see* CONIL, J.M.
SALICE, P. *see* MEIER, C.M.
SALLAS, W.M. *see* HAYASHI, N.
SAMII, K. *see* CONIL, J.M.
SANDERS, N. *see* NEWBOLD, P.
SARGENTINI-MAIER, M.L., ROLAN, P., CONNELL, J., TYTGAT, D., JACOBS, T., PIGEOLET, E., RIETHUISEN, J.-M. & STOCKIS, A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males: 680
SARTORIUS, N. *see* SIM, K.
SAWADA, Y. *see* HORI, S.
SAWADA, Y. *see* ITO, K.
SCHACHTER, M. *see* ARONSON, J.K.
SCHNEIDER, J.A. *see* FIDLER, M.C.
SCHNEIDER, L. *see* KOM, G.D.
SCHUG, B. *see* NASSR, N.
SCHWEDHELM, E. *see* KOM, G.D.
SEBASTIANI, A. *see* COSTAGLIOLA, C.
SEGUIN, T. *see* CONIL, J.M.
SENDEROVITZ, T. *see* TORNØE, C.W.
SEQUEIRA R. *see* PRASAD, K.
SHALANSKY, S.J. *see* GEORGE, J.
SHANKLEY, N.P. *see* GERSKOWITCH, V.P.
SHARMA, R. *see* LI, K.M.
SHEPHARD, E.A. *see* PHILLIPS, I.R.
SHIN, J.-G., KANG, W.-K., SHON, J.-H., AREFAYENE, M., YOON, Y.-R., KIM, K.-A., KIM, D.-I., KIM, D.-S., CHO, K.-H., WOOSLEY, R.L. & FLOCKHART, D.A. Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects: 206
SHINFUKU, N. *see* SIM, K.
SHON, J.-H. *see* SHIN, J.-G.
SI, T. *see* SIM, K.
SILVANI, M.C. *see* POLUZZI, E.
SIM, K., LEE, N.B., CHUA, H.C., MAHENDRAN, R., FUJII, S., YANG, S.-Y., CHONG, M.-Y., SI, T., HE, Y.L., LEE, M.S., SUNG, K.M., CHUNG, E.K., CHAN, Y.H., SHINFUKU, N., TAN, C.H., SARTORIUS, N. & BALDESSARINI, R.J. Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study: 431
SIMONETTI, G.D. *see* MEIER, C.M.
SKOWRON, G., OGDEN, R. & BURGER, D.M. Reverse transcriptase inhibitors in HIV/AIDS therapy: 634
SLAVENBURG, S. *see* HOWARD, R.L.
SMALL, D.S. *see* CHAN, C.
SPEHAR, A. *see* FRENCH, D.D.
STARK, H. *see* MANT, A.
STEWART, A.J. *see* STYPINSKI, D.
STEWART, D. *see* GEORGE, J.
STOCKIS, A. *see* SARGENTINI-MAIER, M.L.
STRAHINJA, P. *see* POLUZZI, E.
STRICKER, B.H.C. *see* VAN DER VELDE, N.
STYPINSKI, D., OBAIDI, M., COMBS, M., WEBER, M., STEWART, A.J. & ISHIKAWA, H. Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers: 459
SUDHAKARAN, S., RAYNER, C.R., LI, J., KONG, D.C.M., GUDE, N.M. & NATION, R.L. Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma: 315
SULLIVAN, J.T. *see* AGORAM, B.
SUN, D.-Q., WANG, H.-S., NI, M.-Y., WANG, B.-J. & GUO, R.-C. Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects: 15
SUNG, K.M. *see* SIM, K.
SUTJANDRA, L. *see* AGORAM, B.
SUTTON, J.A. Nonselective nonsteroidal anti-inflammatory drugs and increased cardiovascular events: stress could be the explanation: 501
SUZUKI, Y. *see* HORI, S.

TACK, I. *see* CONIL, J.M.
TAKAMA, H., TANAKA, H., NAKASHIMA, D., OGATA, H., UCHIDA, E., AKIZAWA, T. & KOSHIKAWA, S. Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration: 300
TAN, C.H. *see* SIM, K.
TANAKA, H. *see* TAKAMA, H.
TANAKA, K. *see* MANT, T.G.K.
TAS, A. *see* VAN DOORN, M.
TEELING, M. *see* USHER, C.
TEOH, R.C. *see* MULRENNAN, S.A.
THOMPSON, P. *see* CHONG, K.T.
TIMBRELL, J. & FLANAGAN, R. The Poison Paradox: 254
TORDOFF, J. *see* BALAKRISHNAN, K.
TORNØE, C.W., AGERSØ, H., SENDEROVITZ, T., NIELSEN, H.A., MADSEN, H., KARLSSON, M.O. & JONSSON, E.N. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic–pituitary–gonadal axis following treatment with GnRH analogues: 648
TRACY, T.S. *see* ZGHEIB, N.K.
TSUKAMOTO, Y. *see* HAYASHI, N.
TURGEON, J. *see* LEFEBVRE, J.
TYTGAT, D. *see* SARGENTINI-MAIER, M.L.

UCHIDA, E. *see* TAKAMA, H.
USHER, C., BENNETT, K., TEELING, M. & FEELY, J. Characterizing new users of NSAIDs before and after rofecoxib withdrawal: 494
USMAN, N.K. *see* ABUBAKAR, I.

VACCHERI, A. *see* POLUZZI, E.
VALLE, M. *see* MOLTÓ, J.
VALTONEN, M. *see* SAARI, T.I.

VAN DEN ANKER, J.N. *see* ANDERSON, B.J.
VAN DER CAMMEN, T.J.M. *see* VAN DER VELDE, N.
VAN DER GREEF, J. *see* VAN DOORN, M.
VAN DER MEER, Y.G. *see* VAN ZANTEN, A.R.H.
VAN DER VELDE, N., CH. STRICKER, B.H.C., POLS, H.A.P. & VAN DER CAMMEN, T.J.M. Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study: 232
VAN DOORN, M., VOGELS, J., TAS, A., VAN HOOGDALEM, E.J., BURGGRAAF, J., COHEN, A. & VAN DER GREEF, J. Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers: 562
VAN GELDER, T. *see* VAN HEST, R.M.
VAN HEST, R.M., VAN GELDER, T., BOUW, R., GOGGIN, T., GORDON, R., MAMELOK, R.D. & MATHOT, R.A. Time-dependent clearance of mycophenolic acid in renal transplant recipients: 741
VAN HOOGDALEM, E.J. *see* VAN DOORN, M.
VAN LUIJN, J.C.F., GRIBNAU, F.W.J. & LEUFKENS, H.G.M. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization: 159
VAN OIJEN, M.G.H., LAHEIJ, R.J.F. & PETERS, W.H.M. Authors' response: Relationships between the adverse effects of aspirin and polymorphisms in genes encoding aspirin metabolizing enzymes: 381
VAN VELDHUISEN, D.J. *see* DOBRE, D.
VAN ZANTEN, A.R.H., OUDIJK, M., NOHLMANS-PAULSSEN, M.K.E., VAN DER MEER, Y.G., GIRBES, A.R.J. & POLDERMAN, K.H. Continuous *vs.* intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/ pharmacodynamics, bacterial susceptibility and clinical efficacy: 100
VANRENTERGHEM, Y. *see* NAESENS, M.
VARGIU, A. *see* POLUZZI, E.
VELLA-BRINCAT, J.W.A., BEGG, E.J., KIRKPATRICK, C.M.J., ZHANG, M., CHAMBERS, S.T. & GALLAGHER, K. Protein binding of cefazolin is saturable *in vivo* both between and within patients: 753
VERBEKE, K. *see* NAESENS, M.
VIAL, T. *see* NGUYEN, K.-A.
VIKTIL, K.K., BLIX, H.S., MOGER, T.A. & REIKVAM, A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems: 187
VISSER, S.T. *see* ATTHOBARI, J.
VITRY, A.I. Comparative assessment of four drug interaction compendia: 709
VOGELS, J. *see* VAN DOORN, M.
VON RICHTER, O. *see* NASSR, N.

WAINWRIGHT, C.E. *see* HENNIG, S.
WALD, N.J. *see* LAW, M.R.
WANG, B.-J. *see* SUN, D.-Q.
WANG, H.-S. *see* SUN, D.-Q.
WANG, M. *see* BLENKINSOPP, A.
WATERHOUSE, T.H. *see* HENNIG, S.
WEBER, M. *see* STYPINSKI, D.
WHELPTON, R. *see* IVERSEN, L.
WHICKER, S. *see* MANT, A.
WILDE, A.A.M. *see* DE BRUIN, M.L.
WILKIE, P. *see* BLENKINSOPP, A.
WINTERS, K.J. *see* JAKUBOWSKI, J.A.
WOLFF, G. *see* MEYER, M.
WOLLMER, P. *see* BONDESSON, E.
WONGP, I.C.K. *see* ACKERS, R.
WOOSLEY, R.L. *see* SHIN, J.-G.
WRISHKO, R.E. *see* FORGUE, S.T.

YAGI, H. *see* HORI, S.
YAMADA-SAWADA, T. *see* MANT, T.G.K.
YAMAMOTO, A. *see* HORI, S.
YANG, S.-Y. *see* SIM, K.
YANO, Y. *see* MANT, T.G.K.
YEO, K.P. *see* CHAN, C.
YOON, Y.-R. *see* SHIN, J.-G.

ZAHLTEN, R. *see* MEYER, M.
ZECH, K. *see* NASSR, N.
ZGHEIB, N.K., FRYE, R.F., TRACY, T.S., ROMKES, M. & BRANCH, R.A. Evaluation of flurbiprofen urinary ratios as *in vivo* indices for CYP2C9 activity: 477
ZHANG, M. *see* VELLA-BRINCAT, J.W.A.
ZHANG, M., HOLMAN, C.D.J., PREEN, D.B. & BRAMELD, K. Repeat adverse drug reactions causing hospitalization in older Australians: a population-based longitudinal study 1980–2003: 163
ZHAO, Q., JIANG, J., LI, X.M., LU, Z.S. & HU, P. Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects: 614
ZUEHLSDORF, M. *see* KUBITZA, D.

SUBJECT INDEX

This index was compiled from the keywords

α_1-adrenoceptor, 665
19-year perspective, 196
ABCB1 (*MDR1*), 53
abortions, 196
absorption, 541
added therapeutic value, 159
adefovir dipivoxil, 15
adherence, 110
adherence to medical regimen, 698
adherence to treatment, 346
ADP, 421
adrenal axis suppression, 288
advanced chronic heart failure, 356
adverse drug reaction, 177, 232
adverse drug reactions (ADRs), 148
adverse drug reactions, 163, 171, 216
adverse effects, 136
aerosol, 722
allometry, 75
ALT, 512
amlodipine, 53
antibiotics, 753
anticonvulsant therapy, 640
anticonvulsants/antiepileptic drugs, 689
antidepressant, 431
antiepileptics, 680
antihypertensive agents, 346
antiretroviral agents, 715
artemisinin, 758
aspirin, 271
asthma, 110, 288
atopic asthma, 548
autoinduction, 758

β-adrenoceptor agonist, 279
β-blockers, 356
β-lactam antibiotics, 100
BAY 59-7939, 469
Bayesian hierarchical model, 595
beclomethasone, 288
belief, 488
benchmarking, 238
bimosiamose, 451
binding model monoclonal antibody, 548
biomarkers, 562
birth defects, 196
bleeding time, 333
blood pressure, 224
BPS Diploma, 385
breast feeding, 322
breast milk, 371
brivaracetam, 680
burn patients, 583

candesartan cilexetil, 628
capecitabine, 67
cardiac arrest, 216
cardiovascular risk, 494
CCK (1) receptors, 618
cefazolin, 753
cefotaxime, 100
cephalosporins, 753
child/adolescent/infant, 689
Chinese subjects, 614
cholecystokinin, 618
Chronic myelogenous leukaemia, 292
clarithromycin, 732
clinical pharmacology, 385
clinical practice, 715
clopidogrel, 421
comparative information, 159
consumers, 148
continuing education, 385
continuous infusion, 100
COPD, 100
coronary artery disease, 698
cortisol suppression, 110
COX-2 inhibitors, 494
CPT, 385
creatinine clearance, 583
cryptosporidiosis, 387
CYP inhibitor, 59
CYP1A2, 310
CYP2C8, 339
CYP2C9, 477
CYP2D6, 310, 575
CYP3A substrate, 365
CYP3A4, 116
cystic fibrosis, 438
cytochrome P450, 116

daily practice, 356
darbepoetin alfa, 41, 300
deoxyuridine, 67
desloratadine, 534
desmethylmirtazapine, 322
dexamphetamine, 371
diabetes, 562
diagnosis, 431
digoxin, 623
Diploma, 385
disease associations, 328
dissertation, 385
dorzolamide, 376
dose, 271, 534
doxazosin, 394
drug absorption, 722
drug concentrations, 715
drug information, 709
drug interaction, 116, 709
drug interactions, 59, 75
drug safety, 136, 163, 238
drug therapy, 136
drug toxicity, 136
drug utilization, 689
drug withdrawal, 232
drug–drug interaction, 365
drug–drug interaction (DDI), 339
drug-related problems, 187
duloxetine, 310

East Asia, 431
educational interventions, 92
elderly, 163, 171, 177
EMEA, 159
emphysema, 527
enrichment strategy, 595
EPAR, 159
epilepsy, 614, 689
erectile dysfunction, 24
ethnicity, 206, 328
exercise, 279

Factor Xa inhibitor, 469
fall-risk-increasing drugs, 232
FcγR, 328
fentanyl, 121
fluconazole, 59, 477
flurbiprofen, 477
formulations, 85
fracture, 238
fructose, 404

gallbladder, 618
gastric emptying, 541
gender, 206
general practice, 494
genetic polymorphism, 328
geriatric medicine, 232
geriatrics, 238
Ginkgo biloba, 333
glibenclamide, 732
glomerular filtration rate, 224, 583
GnRH agonist triptorelin, 648
GnRH receptor blocker degarelix, 648
grapefruit juice, 732

healthy Chinese subject, 15
healthy volunteers, 333
heart failure, 488
heart rate, 279
herb–drug interactions, 258

© 2007 Blackwell Publishing Ltd

HIV protease inhibitors, 315
HIV-infection, 715
hormonal contraceptives, 224
hospitalization, 171
hospitalized patients, 187
human milk, 322
hypertension, 575, 628
hypoglycaemic agents, 346
hypothalamic–pituitary–gonadal axis, 648

ibuprofen, 271
IgE, 548
immunosuppression, 459
inappropriate medication, 177
indinavir, 315
infant dose, 322, 371
infant well-being, 322, 371
inhalation, 451
inhaled steroids, 110
inhibitor, 477
in-hospital, 216
interindividual variability, 715
intraocular pressure, 376
intravenous, 300
irbesartan, 628
isoprostanes, 672
isotretinoin use, 196
itraconazole, 438

juvenile primary open-angle glaucoma, 376

Keppra, 614
ketoconazole, 59
knowledge, 92

lasofoxifene, 59
levetiracetam, 614
linked data, 163
lipid-lowering agents, 346
lipoprotein-associated phospholipase, 672
longitudinal study, 163
losartan, 628
lung deposition, 722

male genital tract pharmacology, 404
management, 640
matrix metalloproteinase, 512
matrix transdermal delivery system, 121
medication, 171, 488
medication errors, 136
medicines, 85
meta-analysis, 387, 640
metabolomics, 562
metabonomics, 562
methamphetamine, 10
midazolam, 365
milnacipran, 665
mirtazapine, 322
mizoribine, 459
modelling placebo response, 595
monitoring, 623
montelukast, 339
Morisky, 488
mortality, 356
mucociliary clearance, 722
mycophenolic acid pharmacokinetics, 541
mycophenolic acid, 741

nasal decongestant, 10
nebivolol, 575
new active substance, 159
nitrates, 346
NMR, 562
non-adherence, 488
nonlinear mixed-effects models, 292
NONMEM, 300, 548, 648
nonselective NSAIDs, 494
norepinephrine reuptake inhibition, 665
NSAID, 469
nucleosides, 67

OATP2B1, 732
off label, 85
older persons, 232
optimal design, 438
oral anticoagulant, 469
oxidative stress, 672

$P2Y_{12}$, 421
paediatric, 85, 534
pain, 271
palatability, 628
paracetamol, 271
paroxetine, 59
patients, 148
PDE4 inhibitor, 365
PEG-Intron, 292
performance, 121
P-glycoprotein, 53, 732
pharmacodynamic interaction, 333
pharmacodynamic marker, 67
pharmacodynamics, 100, 394, 680
pharmacoepidemiology, 238, 689
pharmacogenetics, 53
pharmacokinetics, 15, 24, 53, 75, 100, 121, 310, 315, 394, 451, 459, 512, 527, 534, 614, 618, 680, 722, 732, 741, 758
pharmacovigilance, 148, 238
pharmakokinetics, 365
phase I, 512
Phase I trial, 451
phenylephrine, 10
phosphodiesterase, 24
piloerection, 665
plasma cysteamine, 36
platelet aggregation inhibitors, 421
platelet aggregation, 333
polymorphism, 53
polypharmacy, 187
population-based study, 196
population pharmacokinetics, 41, 292, 300, 438
population PK/PD modelling, 648
posterior probability, 595
prasugrel, 421
prediction equations, 583
prednisolone, 110
pregnancies, 196
pregnancy, 315
premature infants, 75
prescribing database, 494
primary health care, 346
probe drug, 477
professional development, 385
prostate specific antigen, 404
prostate, 404
protein binding, 315, 753
protein-binding, 618
pseudoephedrine, 10

QT interval, 279
QT prolongation, 206
QTc prolongation, 216
quality of health care services, 623
quinidine, 206

R667, 527
race, 310
randomized active-control trial, 159
rational drug use, 92
receptor occupancy, 665
receptor-binding, 394
refill, 488
renal transplant, 459
renal transplantation, 741
reporting, 148
response, 271
retinal blood flow, 376
risk management, 258
risk, 171
rivaroxaban, 469
ROC curve analysis, 595
roflumilast, 365
rosiglitazone, 339

S-3304, 512
safety and tolerability, 451
safety, 15, 121, 459, 512
saquinavir, 315
secretory phospholipases, 672
selectin, 451
semen, 404
semen vesicle, 404
serum creatinine, 583
sheltered housing, 171
sibenadet, 279
side effects, 148
statins, 698
status epilepticus, 640
subject specific correction factor, 279
syncope, 232
systematic PK/PD model building framework, 648
systematic review, 136, 387

tadalafil, 24
tandem mass spectrometry, 36
technetium-99 m, 722
teenagers, 92
telmisartan, 628
therapeutic drug monitoring, 541

therapeutics, 328, 385, 387
thienopyridine, 421
thymidine, 67
time-dependent clearance, 741
timolol, 376
tolerance, 15
treatment, 431
TS inhibition, 67
ucb 34714, 680
ucb L059, 614
unlicensed, 85
urinary albumin excretion, 224
valsartan, 628
vancomycin, 75
voriconazole, 116
workshops, 385
zolpidem, 116

Contents

Volume 63, Number 1, January 2007

Editors' view

1 Editors' review of 2006 and the BJCP prize: *J.K. Aronson, M.S. Lennard, J.M. Ritter, E.J. Begg, L.D. Lewis, M. Schachter*

Commentary

5 Education for new prescribers: a summary of the proceedings of a symposium held at The British Pharmacological Society, December 2005: *H.L. Leathard, M. Abbott, M. Brownsell, M. Lennard & S. Maxwell*

Review

10 Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse: *R. Eccles*

Pharmacokinetics & pharmacodynamics

15 Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects: *D.-Q. Sun, H.-S. Wang, M.-Y. Ni, B.-J. Wang & R.-C. Guo*

Pharmacokinetics

24 Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics: *S.T. Forgue, D.L. Phillips, A.W. Bedding, C.D. Payne, H. Jewell, B.E. Patterson, R.E. Wrishko & M.I. Mitchell*

36 Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion: *M.C. Fidler, B.A. Barshop, J.A. Gangoiti, R. Deutsch, M. Martin, J.A. Schneider & R. Dohil*

41 Population pharmacokinetics of darbepoetin alfa in healthy subjects: *B. Agoram, L. Sutjandra & J.T. Sullivan*

Pharmacogenetics

53 Effect of *ABCB1* (*MDR1*) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects: *K.-A. Kim, P.-W. Park & J.-Y. Park*

Drug interactions

59 Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene: *D. Ouellet, C. Bramson, D. Roman, A.E. Remmers, E. Randinitis, A. Milton & M. Gardner*

67 Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients: *K.M. Li, L.P. Rivory, J. Hoskins, R. Sharma & S.J. Clarke*

75 Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance: *B.J. Anderson, K. Allegaert, J.N. Van den Anker, V. Cossey & N.H.G. Holford*

Pharmacoepidemiology

85 Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998–2002: *K. Balakrishnan, J. Tordoff, P. Norris & D. Reith*

Pharmacovigilance

92 Long-term effects of an educational intervention on self-medication and appropriate drug use in single-sex secondary public schools, Quito, Ecuador: *J.-C. Maldonado, S.D. Meléndez & A. Figueras*

Therapeutics

100 Continuous *vs.* intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy: *A.R.H. van Zanten, M. Oudijk, M.K.E. Nohlmans-Paulssen, Y.G. van der Meer, A.R.J. Girbes & K.H. Polderman*

110 A cross-sectional study evaluating the relationship between cortisol suppression and asthma control in patients with difficult asthma: *S. AbuRuz, L.G. Heaney, J. Millership, J. Gamble & J. McElnay*

Short reports

116 Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects: *T.I. Saari, K. Laine, K. Leino, M. Valtonen, P.J. Neuvonen & K.T. Olkkola*

121 Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation: *J.-F. Marier, M. Lor, J. Morin, L. Roux, M. Di Marco, G. Morelli & E.A. Sædder*

Letters to the editors

125 Statins down under: *A. Mant, J. Lowinger, W. Hall, S. Whicker, C. Ringland & H. Stark*

128 Amitriptyline for clozapine-induced nocturnal enuresis and sialorrhoea: *S.K. Praharaj & M. Arora*

Volume 63, Number 2, February 2007

Editors' view

131 Adverse drug reactions – no farewell to harms: *J.K. Aronson*

Systematic reviews

136 Which drugs cause preventable admissions to hospital? A systematic review: *R.L. Howard, A.J. Avery, S. Slavenburg, S. Royal, G. Pipe, P. Lucassen & M. Pirmohamed*

148 Patient reporting of suspected adverse drug reactions: a review of published literature and international experience: *A. Blenkinsopp, P. Wilkie, M. Wang & P.A. Routledge*

157 Calcium channel blockers and headache: *M.R. Law, J.K. Morris & N.J. Wald*

Clinical trials

159 Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization: *J.C.F. van Luijn, F.W.J. Gribnau & H.G.M. Leufkens*

Susceptibility factors for adverse effects

163 Repeat adverse drug reactions causing hospitalization in older Australians: a population-based longitudinal study 1980–2003: *M. Zhang, C.D.J. Holman, D.B. Preen & K. Brameld*

171 Risk factors for medication misadventure among residents in sheltered housing complexes: *J. George, K. Munro, D. McCaig & D. Stewart*

177 Is inappropriate medication use a major cause of adverse drug reactions in the elderly?: *M.-L. Laroche, J.-P. Charmes, Y. Nouaille, N. Picard & L. Merle*

187 Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems: *K.K. Viktil, H.S. Blix, T.A. Moger & A. Reikvam*

196 Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective: *A. Bérard, L. Azoulay, G. Koren, L. Blais, S. Perreault & D. Oraichi*

206 Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects: *J.-G. Shin, W.-K. Kang, J.-H. Shon, M. Arefayene, Y.-R. Yoon, K.-A. Kim, D.-I. Kim, D.-S. Kim, K.-H. Cho, R.L. Woosley & D.A. Flockhart*

Specific adverse effects

216 In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs: *M.L. De Bruin, P.N.J. Langendijk, R.P. Koopmans, A.A.M. Wilde, H.G.M. Leufkens & A.W. Hoes*

224 The impact of hormonal contraceptives on blood pressure, urinary albumin excretion and glomerular filtration rate: *J. Atthobari, R.T. Gansevoort, S.T. Visser, P.E. de Jong & L.T.W. de Jong-van den Berg on behalf of the PREVEND study group*

232 Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study: *N. van der Velde, B.H. Ch. Stricker, H.A.P. Pols & T.J.M. van der Cammen*

238 National outpatient medication profiling: medications associated with outpatient fractures in community-dwelling elderly veterans: *D.D. French, R. Campbell, A. Spehar, L.Z. Rubenstein, L.G. Branch & F. Cunningham*

245 Safety of computerized drug management: a case report: *K.-A. Nguyen, T. Vial, F. Gueyffier, S. Marignier, P. Cochat & B. Kassaï for the Paediatric Pharmacovigilance Working Group*

247 Herbal medicines and acute medical emergency admissions to hospital: *S. Constable, A. Ham & M. Pirmohamed*

249 The combination of nuclear and mitochondrial mutations as a risk factor for idiosyncratic toxicity: *D. LaRocca, D.F. Lehmann, A. Perl, T. Ozawa & P.D. Holohan*

252 A rare cause of finger clubbing in a life-long nonsmoker: *G.P. Currie, A. Niruban & O.J. Dempsey*

253 Dysgeusia with amlodipine – a case report: *B. Sadasivam & R. Jhaj*

Book review

254 The Poison Paradox: *Edited by J. Timbrell; reviewed by R. Flanagan*

Volume 63, Number 3, March 2007

Editors' view

255 Concentration-effect and dose-response relations in clinical pharmacology: *J.K. Aronson*

Review

258 Clinical risk management of herb–drug interactions: *P.A.G.M. De Smet*

Editorial commentary

268 Dose–response of minor analgesics in acute pain: *A. Li Wan Po*

Pharmacodynamics

271 Dose–response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies: *H.J. McQuay & R.A. Moore*

279 Lack of correlation between exercise and sibenadet-induced changes in heart rate corrected measurement of the QT interval: *P. Newbold, N. Sanders & S.B. Reele*

288 Adrenal axis suppression unrelated to the dynamics of dosing with beclomethasone monopropionate: *S.A. Mulrennan, J.S. Hogg, R.C. Teoh & A.H. Morice*

Pharmacokinetics

292 Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia: *S. Gupta, J. Jen, K. Kolz & D. Cutler*

300 Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration: *H. Takama, H. Tanaka, D. Nakashima, H. Ogata, E. Uchida, T. Akizawa & S. Koshikawa*

310 Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects: *C. Chan, K.P. Yeo, A.X. Pan, M. Lim, M.P. Knadler & D.S. Small*

Paediatric pharmacokinetics

315 Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma: *S. Sudhakaran, C.R. Rayner, J. Li, D.C.M. Kong, N.M. Gude, & R.L. Nation*

322 Transfer of the antidepressant mirtazapine into breast milk: *J.H. Kristensen, K.F. Ilett, J. Rampono, R. Kohan & L.P. Hackett*

Pharmacogenetics

328 Distribution of the FcγRIIIa 176 F/V polymorphism amongst healthy Chinese, Malays and Asian Indians in Singapore: *K.T. Chong, W.F. Ho, S.H. Koo, P. Thompson & E.J.D. Lee*

Interactions

333 Pharmacodynamic interaction studies of *Ginkgo biloba* with cilostazol and clopidogrel in healthy human subjects: *D. Aruna & M.U.R. Naidu*

339 Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans: *K.-A. Kim, P.-W. Park, K.R. Kim & J.-Y. Park*

Therapeutics

346 Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage: *E. Poluzzi, P. Strahinja, A. Vaccheri, A. Vargiu, M.C. Silvani, D. Motola, G. Marchesini, F. De Ponti & N. Montanaro*

356 Effectiveness of β-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age?: *D. Dobre, M.J.L. DeJongste, C. Lucas, G. Cleuren, D.J. van Veldhuisen, A.V. Ranchor & F. Haaijer-Ruskamp*

Short reports

365 Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects: *N. Nassr, G. Lahu, O. von Richter, F. Reutter, D. Knoerzer, K. Zech, K.A. Erb, B. Schug, H. Blume & R. Hermann*

371 Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder: *K.F. Ilett, L.P. Hackett, J.H. Kristensen & R. Kohan*

376 Effect of 2% dorzolamide on retinal blood flow: a study on juvenile primary open-angle glaucoma patients already receiving 0.5% timolol: *C. Costagliola, C. Campa, F. Parmeggiani, C. Incorvaia, P. Perri, S. D'Angelo, G. Lamberti & A. Sebastiani*

Letters to the Editors

380 Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes: *J.O. Miners & R.O. Day*

381 Authors' response: Relationships between the adverse effects of aspirin and polymorphisms in genes encoding aspirin metabolizing enzymes: *M.G.H. van Oijen, R.J.F. Laheij & W.H.M. Peters*

Volume 63, Number 4, April 2007

Editors' view

383 Compliance, concordance, adherence: *J.K. Aronson*

Editorial

385 The BPS Diploma in Advanced Pharmacology: a training opportunity for clinical pharmacologists: *J.M. Hall*

Systematic review

387 Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis: *I. Abubakar, S.H. Aliyu, C. Arumugam, N.K. Usman & P.R. Hunter*

Pharmacodynamics

394 Assessment of α_1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory: *K. Ito, H. Ohtani & Y. Sawada*

404 A new method to estimate quantitatively seminal vesicle and prostate gland contributions to ejaculate: *T.T. Ndovi, T. Parsons, L. Choi, B. Caffo, C. Rohde & C.W. Hendrix*

421 A multiple dose study of prasugrel (CS-747), a novel thienopyridine $P2Y_{12}$ inhibitor, compared with clopidogrel in healthy humans: *J.A. Jakubowski, N. Matsushima, F. Asai, H. Naganuma, J.T. Brandt, T. Hirota, S. Freestone & K.J. Winters*

Therapeutics

431 Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study: *K. Sim, N.B. Lee, H.C. Chua, R. Mahendran, S. Fujii, S.-Y. Yang, M.-Y. Chong, T. Si, Y.L. He, M.S. Lee, K.M. Sung, E.K. Chung, Y.H. Chan, N. Shinfuku, C.H. Tan, N. Sartorius & R.J. Baldessarini*

Pharmacokinetics

438 A D-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients: *S. Hennig, T.H. Waterhouse, S.C. Bell, M. France, C.E. Wainwright, H. Miller, B.G. Charles & S.B. Duffull*

451 Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males: *M. Meyer, K.-M. Beeh, J. Beier, D. Beyer, E. Aydt, R. Zahlten, B. Jilma & G. Wolff*

459 Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers: *D. Stypinski, M. Obaidi, M. Combs, M. Weber, A.J. Stewart & H. Ishikawa*

Drug interactions

469 Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen: *D. Kubitza, M. Becka, W. Mueck & M. Zuehlsdorf*

Pharmacogenetics

477 Evaluation of flurbiprofen urinary ratios as *in vivo* indices for CYP2C9 activity: *N.K. Zgheib, R.F. Frye, T.S. Tracy, M. Romkes & R.A. Branch*

Short reports

488 Predictors of refill non-adherence in patients with heart failure: *J. George & S.J. Shalansky*

494 Characterizing new users of NSAIDs before and after rofecoxib withdrawal: *C. Usher, K. Bennett, M. Teeling & J. Feely*

Letters to the Editors

498 Prokinetic therapy with erythromycin has no significant impact on blood pressure and heart rate in critically ill patients: *N.Q. Nguyen, A.A. Mangoni, R.J. Fraser, M. Chapman, L. Bryant, C. Burgstad & R.H. Holloway*

501 Nonselective nonsteroidal anti-inflammatory drugs and increased cardiovascular events: stress could be the explanation: *J.A. Sutton*

502 Authors' reply: Nonselective nonsteroidal anti-inflammatory drugs and increased cardiovascular events: stress could be the explanation: *C.J. Hawkey*

502 Authors' reply: Nonselective nonsteroidal anti-inflammatory drugs and increased cardiovascular events: emotional stress could be the explanation: *K.M. Knights, A.A. Mangoni & J.O. Miners*

503 Proceedings of the Dutch Society of Clinical Pharmacology and Biopharmacy meeting of September 27th 2006

Volume 63, Number 5, May 2007

Editors' view

509 Drug therapy in kidney disease: *J.K. Aronson*

Pharmacokinetics

512 Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers: *T.G.K. Mant, D. Bradford, D.M. Amin, J. Pisupati, Y. Kambayashi, Y. Yano, K. Tanaka & T. Yamada-Sawada*

527 Pharmacokinetics of a novel agent, R667, in patients with emphysema: *Y.-Y. Chiu, M.D. Roth, S. Kolis, D. Rogovitz & B. Davies*

534 Pharmacokinetics of desloratadine in children between 2 and 11 years of age: *S. Gupta, S. Khalilieh, B. Kantesaria & C. Banfield*

541 Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients: *M. Naesens, K. Verbeke, Y. Vanrenterghem & D. Kuypers*

Pharmacokinetics & pharmacodynamics

548 A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab: *N. Hayashi, Y. Tsukamoto, W.M. Sallas & P.J. Lowe*

Drug metabolism

562 Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers: *M. van Doorn, J. Vogels, A. Tas, E.J. van Hoogdalem, J. Burggraaf, A. Cohen & J. van der Greef*

Therapeutics

575 The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension: *J. Lefebvre, L. Poirier, P. Poirier, J. Turgeon & Y. Lacourciere*

583 Assessment of renal function in clinical practice at the bedside of burn patients: *J.M. Conil, B. Georges, O. Fourcade, T. Seguin, M. Lavit, K. Samii, G. Houin, I. Tack & S. Saivin*

Experimental medicine

595 Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials: *R. Gomeni & E. Merlo-Pich*

Short reports

614 Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects: *Q. Zhao, J. Jiang, X.M. Li, Z. (Sarah) Lu & P. Hu*

618 Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist: *V.P. Gerskowitch, J. Hodge, R.A.D. Hull, N.P. Shankley, S.B. Kalindjian, J. McEwen & J.W. Black*

623 Quality of requests for serum digoxin concentrations: experience from an Australian Regional Health Service: *C. Ellington, N. Grgurinovich, J.O. Miners & A.A. Mangoni*

628 Palatability of angiotensin II antagonists among nephropathic children: *C.M. Meier, G.D. Simonetti, S. Ghiglia, E. Fossali, P. Salice, C. Limoni & M.G. Bianchetti, CHIld Project*

Letters to the Editors

632 Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment: *M. Fenske*

633 Authors' response: Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment: *Y.-C. Chen, A.N. Nafziger, J.S. Bertino & A.D.M. Kashuba*

Book review

634 Reverse transcriptase inhibitors in HIV/AIDS therapy: *Edited by G. Skowron & R. Ogden; reviewed by D.M. Burger*

635 Erratum

Volume 63, Number 6, June 2007

Editors' view

637 Communicating information about drug interactions: *J.K. Aronson*

Review

640 Anticonvulsant therapy for status epilepticus: *K. Prasad, P.R. Krishnan, K. Al-Roomi & R. Sequeira*

Pharmacodynamics

648 Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic–pituitary–gonadal axis following treatment with GnRH analogues: *C.W. Tornøe, H. Agersø, T. Senderovitz, H.A. Nielsen, H. Madsen, M.O. Karlsson & E.N. Jonsson*

665 Piloerection induced by replacing fluvoxamine with milnacipran: *S. Hori, N. Matsuo, A. Yamamoto, T. Hazui, H. Yagi, M. Nakano, Y. Suzuki, A. Miki, H. Ohtani & Y. Sawada*

672 Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F^{2trans}-isoprostane in hypercholesterolaemic patients: *G.D. Kom, E. Schwedhelm, R. Maas, L. Schneider, R. Benndorf & R.H. Böger*

680 The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males: *M.L. Sargentini-Maier, P. Rolan, J. Connell, D. Tytgat, T. Jacobs, E. Pigeolet, J.-M. Riethuisen & A. Stockis*

Theraputics

689 Prioritizing children's medicines for research: a pharmacoepidemiological study of antiepileptic drugs: *R. Ackers, M.L. Murray, F.M.C. Besag & I.C.K. Wong*

698 Impact of adherence to statins on coronary artery disease in primary prevention: *M.-H. Bouchard, A. Dragomir, L. Blais, A. Bérard, D. Pilon & S. Perreault*

709 Comparative assessment of four drug interaction compendia: *A.I. Vitry*

Pharmacokinetics

715 Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice: *J. Moltó, A. Blanco, C. Miranda, J. Miranda, J. Puig, M. Valle, M. DelaVarga, C.R. Fumaz, M.J. Barbanoj & B. Clotet*

722 Site of deposition and absorption of an inhaled hydrophilic solute: *E. Bondesson, T. Bengtsson, L.-E. Nilsson & P. Wollmer*

732 Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide: *J.J. Lilja, M. Niemi, H. Fredrikson & P.J. Neuvonen*

741 Time-dependent clearance of mycophenolic acid in renal transplant recipients: *R.M. van Hest, T. van Gelder, R. Bouw, T. Goggin, R. Gordon, R.D. Mamelok & R.A. Mathot*

753 Protein binding of cefazolin is saturable *in vivo* both between and within patients: *J.W.A. Vella-Brincat, E.J. Begg, C.M.J. Kirkpatrick, M. Zhang, S.T. Chambers & K. Gallagher*

Short report

758 Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model: *S. Asimus & T. Gordi*

Book reviews

763 Speed, Ecstasy, Ritalin: The Science of Amphetamines: *L. Iversen; reviewed by R. Whelpton*

764 Cytochrome P450 Protocols, 2nd edn: *Edited by I.R. Phillips & E.A. Shephard; reviewed by M. Lennard*

Obituary

765 Robert William Kerwin: *R. Sainz-Fuertes*

767 Proceedings of the British Pharmacological Society 75th Anniversary Meeting Clinical Pharmacology Section 18–21 December 2006

793 Author Index

799 Subject Index

v Volume Contents